To this end, we used the immunogenic TRAMP-C1 progressor prostate carcinoma cell line, which harbors a distinct mutated neoepitope of the SPAS-1 protein recognized by CD8+ T cells (30). This evidence concerns the gene CD8A and prostate carcinoma.